Pelacarsen Roll-over Extension Program
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 599 participants.
Also called NCT06875973
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 599 participants
- Sponsor
- Registry
-
NCT06875973
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Puerto Rico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06875973. Allocation not applicable; no masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2030-12-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pelacarsen Roll-over Extension Program
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Pelacarsen (TQJ230)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06875973- Content hash
1d05c704d12db076f7d428c3bcc5ab1043d1e2abcefa962d7657edd59459d880